contadores web
Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Scientific and technological research article

Vol. 21 No. 3 (2019)

Quality of life of patients with multiple sclerosis treated at a health institution in Medellín (Colombia)

DOI
https://doi.org/10.22267/rus.192103.159
Submitted
January 23, 2018
Published
2019-08-31

Abstract

Introduction: Health-related quality of life (HRQL) in multiple sclerosis (MS) patients can be affected by physical, clinical and sociodemographic factors. Objective: To determine the effect of sociodemographic, clinical and physical factors on the quality of life (QL) of patients with MS. Materials and methods: The WHO WHOQOL-BREF instrument was applied to 173 patients of a health institution. Descriptive analysis of sociodemographic, clinical and physical characteristics and their QL scores were performed. The association between global QL with sociodemographic, clinical and physical factors was observed; finally, through multivariate analysis. Results: 80.3% were women, the median age was 43 years (IQR = 51-35). Fatigue was the most frequent symptom (71%). The risk factors for worse QL were: female sex (RP = 6.92. 95% CI 1.8-26.58), abnormal sphincter control (RP = 6.10 95% CI 1.26-29.51), cognitive disorders (RP = 4.46 95% CI 1.07-18.56), risk of depression (RP = 3.82 95% CI 1 , 01-14,38) and lack of physiotherapy (RP = 4.48 95% CI 1.08-18.34). Conclusions: The effect of QL in MS is variable and depends on sociodemographic and clinical factors. Evaluating the (HRQL) in clinical practice facilitates the understanding of the behavior and needs of the patient required for risk factors intervention.

References

  1. Kidd T, Carey N, Mold F. A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life. PLoS One. 2017;12(10):e0185931.
  2. Browne P, Chandraratna D, Angood C. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022–4.
  3. Montalban X, Gold R, Thompson AJ. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018;24(2):96–120.
  4. Hart FM, Bainbridge J. Current and emerging treatment of multiple sclerosis. Am J Manag Care. 2016;22(6):159–70.
  5. Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017;65(5):883–91.
  6. Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017;65(5):883–91.
  7. Fernández O, Baumstarck-Barrau, Karine S. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: Assessment using the MusiQoL and SF-36 questionnaires. Mult Scler J. 2011;17(10):1238–49.
  8. Baumstarck K, Pelletier J, Butzkueven H. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2013;20(6):907–14.
  9. Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics. 2009;27(8):681-91.
  10. Cores E V, Vanotti S, Burin DI. Factores asociados con la situación laboral de pacientes con esclerosis múltiple TT - Factors associated to the work situation of patients with multiple sclerosis. Rev Neurol. 2014;58(4):175–83.
  11. Patti F. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Mult Scler. 2007;13(6):783–91.
  12. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005;231(1–2):29–34.
  13. Olascoaga J. Calidad de vida y esclerosis múltiple. Rev Neurol. 2010;51(5):279–88.
  14. Simeoni MC, Auquier P, Fernandez O et al. Validation of the Multiple Sclerosis International. Mult Scler. 2008;14(April 2007):219–30.
  15. Fernández O, Fernández V, Baumstarck-Barrau. Validation of the spanish version of the multiple sclerosis international quality of life (musiqol) questionnaire. BMC Neurol. 2011;11(1):127.
  16. Boucher F, Baumstarck K, Acquadro C. Challenges In Translating The Multiple Sclerosis International Quality of Life (Musiqol) Questionnaire In 57 Languages. Value Heal. 2015;18(7):A762.
  17. Gracia F, Larreategui M, Rodríguez G. Costs of multiple sclerosis in Panama from societal, patient perspectives and healthrelated quality of life. PLoS One. 2018;13(10):1–12.
  18. WHOQOL. Development of the WHOQOL: Rationale and Current Status. Int J Ment Health. 2014;23(3):24–56.
  19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1444.
  20. William WK, Zung MD. A self rating depression scale. Arch gen psych. 1965;12:63–70.
  21. William WK. Factors influencing the Self-Rating Depression Scale. Arch Gen Psychiat. 1967;16:543–7.
  22. Campo-Arias A. Comparación de algunas propiedades psicométricas de la escala de Zung para depresión con puntuaciones dicotómicas. Rev Colomb Psiquiatr. 2006;35(4):511–8.
  23. Campo-Arias A, Díaz-Martínez LA, Rueda-Jaimes GE. Validación de la escala de Zung para depresión en universitarias de Bucaramanga, Colombia Validation of Zung’s Self-Rating Depression Scale Among Universitary Student Women from Bucaramanga , Colombia. Rev Colomb Psiquiatr. 2005;34(1):54–62.
  24. Polman CH, Reingold SC. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
  25. Alan J Thompson, Brenda L Banwell FB. Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017. Lancet Neurol. 2018;89(17):162–73.
  26. Salter AR, Cutter GR, Tyry T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. 2010;26(2):493–500.
  27. De DEM. Informe mundial sobre el empleo y la EM 2016. 2016;1–3.
  28. Smith C, Hale L, Olson K. How does exercise influence fatigue in people with multiple sclerosis. Disabil Rehabil. 2009;31(9):685–92.
  29. Freeman JA, Hendrie W, Creanor S. Standing up in multiple sclerosis (SUMS): Protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis. BMC Neurol. 2016;16(1):1–10.
  30. Benito-León J, Mitchell AJ, Rivera-Navarro J. Impaired health-related quality of life predicts progression of disability in multiple sclerosis. Eur J Neurol. 2013;20(1):79–86.
  31. Wilski M, Tasiemski T. Health-related quality of life in multiple sclerosis: role of cognitive appraisals of self, illness and treatment. Qual Life Res. 2016;25(7):1761–70.
  32. Yalachkov Y, Soydaş D, Bergmann J. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2019;30(January):33–7.
  33. Wang Y, Gorenstein C. Assessment of depression in medical patients: A systematic review of the utility of the Beck Depression Inventory-II. Clinics. 2013;68(9):1274–87.
  34. Tepavčević DK, Pekmezović T, Drulović J. Quality of life assessment in patients with multiple sclerosis | Ispitivanje kvaliteta života bolesnika sa multiplom sklerozom. Vojnosanit Pregl. 2009;66(8):645–51.
  35. Arnett P, Ben-Zacharia A, Benedict R. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11(3):328–37.
  36. Sánchez-López MP, Olivares-Pérez T, Nieto-Barco A. Esclerosis múltiple y depresión. Rev Neurol. 2004;38(6):524–9.
  37. Hale LA, Smith C, Mulligan H. Tell me what you want, what you really really want..: Asking people with multiple sclerosis about enhancing their participation in physical activity. Disabil Rehabil. 2012;34(22):1887–93.
  38. Tabrizi FM, Radfar M. Fatigue, sleep quality, and disability in relation to quality of life in multiple sclerosis. Int J MS Care. 2015;17(6):268–74.
  39. Virtanen A, Ruutiainen J, Aunola S. Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study. Neurology. 2004;63(11):2034–8.
  40. Halabchi F, Alizadeh Z, Sahraian MA. Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol. 2017;17(1):1–11.
  41. Dalgas U. Exercise therapy in multiple sclerosis and its effects on function and the brain. Neurodegener Dis Manag. 2017;7(6):35–40.

Downloads

Download data is not yet available.

Most read articles by the same author(s)